术前MRI特征与临床实验室指标预测肝细胞癌经导管动脉化疗栓塞联合高强度聚焦超声治疗早期疗效
本研究纳入2011年1月至2017年6月接受TACE/HIFU治疗的188例患者共223个肿瘤,按RECICL 2015标准分为完全缓解组与未完全缓解组,评估术前MRI特征和实验室指标对早期疗效的预测价值并建立预测模型。2-5 cm组边缘不规则与早期未完全缓解密切相关;>5 cm组边缘不规则、动脉期瘤周强化及AFP异常为独立预测因子。结论认为上述特征可用于预测HCC对TACE/HIFU治疗的早期反应。
要点
- 2-5 cm肝细胞癌边缘不规则与TACE/HIFU治疗后早期未完全缓解密切相关。
- >5 cm肿瘤中边缘不规则、动脉期瘤周强化及AFP异常为早期未完全缓解的独立预测因子。
- 基于术前常规MRI特征与实验室指标可预测TACE/HIFU治疗后未完全缓解高风险。
核心结论
- 2-5 cm肿瘤边缘不规则以及>5 cm肿瘤的边缘不规则、动脉期瘤周强化和AFP异常可用于预测HCC对TACE/HIFU治疗的早期反应。
- 多特征联合可预测未完全缓解高风险。
研究设计与样本
- 回顾性纳入2011年1月至2017年6月接受TACE/HIFU治疗的188例患者共223个肿瘤。
- 肿瘤按大小分为<2 cm、2-5 cm、>5 cm三组,按RECICL 2015修订版标准分为未完全缓解组与完全缓解组。
- 采用单因素分析和多因素logistic回归确定独立预测因子,以ROC曲线评估各预测因子的诊断效能。
- 预测模型基于多因素回归分析的β系数构建。
关键影像表现/征象
- 2-5 cm组中边缘不规则与早期未完全缓解密切相关。
- >5 cm组中边缘不规则、动脉期瘤周强化及AFP异常为早期未完全缓解的独立预测因子。
诊断标准与关键数值
- 疗效评估采用RECICL 2015修订版标准,分为完全缓解与未完全缓解。
- 预测模型提示:边缘不规则联合动脉期瘤周强化、AFP异常联合边缘不规则和动脉期瘤周强化均预测早期未完全缓解风险增加。
临床应用与阅片要点
- 术前常规MRI特征和实验室指标无需复杂后处理即可获取,可基于其预测HCC经TACE/HIFU治疗后的疗效反应。
- 多特征联合可识别未完全缓解高风险患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To evaluate the value of preoperative MRI features and laboratory indicators in predicting the early response of hepatocellular carcinoma (HCC) to transcatheter arterial chemoembolization (TACE) combined with high-intensity focused ultrasound (HIFU) treatment and to establish a preoperative prediction model.
METHODS: A total of 188 patients with 223 tumors who underwent TACE/HIFU treatment from January 2011 to June 2017 were included. Tumors were divided into three groups (< 2 cm, 2 - 5 cm,> 5 cm) and classified as non-complete response (NCR) and complete response (CR) cohorts according to the Response Evaluation Criteria in Cancer of the Liver (RECICL) 2015 revised version. Univariate analysis and multivariate logistic regression analysis were used to determine independent predictors, and receiver operating characteristic (ROC) curve analysis was performed to assess the diagnostic power of each predictor. The prediction model was derived on the β coefficient of the multivariate regression analysis of the predictors.
RESULTS: Irregular margins in the 2 - 5 cm group were closely related to early NCR. Irregular margins, arterial peritumoral enhancement and abnormal alpha-fetoprotein (AFP) were independent predictors of early NCR in the > 5 cm group. The prediction model of this group suggests that irregular margins combined with arterial peritumoral enhancement and abnormal AFP combined with irregular margins and arterial peritumoral enhancement predict an increased risk of early NCR.
CONCLUSION: Irregular margins of 2 - 5 cm tumors and irregular margins, arterial peritumoral enhancement, and abnormal AFP of tumors > 5 cm can be applied to predict the early response of HCC to TACE/HIFU treatment.
ADVANCES IN KNOWLEDGE: TACE combined with HIFU treatment may be able to significantly improve survival in patients with advanced HCC. Conventional MRI features and laboratory indicators are readily available without complex post-processing. It is feasible to predict the response of HCC after TACE/HIFU treatment based on preoperative conventional MRI features and laboratory indicators, the combination of multiple features predicts high-risk of non-complete response.
引用
- Zhang H, He X, Yu J, et al. Preoperative MRI features and clinical laboratory indicators for predicting the early therapeutic response of hepatocellular carcinoma to transcatheter arterial chemoembolization combined with High-intensity focused ultrasound treatment. Br J Radiol. 2019. PMID: 31166700. doi:10.1259/bjr.20190073
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。